An international MDS/MPN working group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms

Tariq I. Mughal, Nicholas C.P. Cross, Eric Padron, Ramon V. Tiu, Michael Savona, Luca Malcovati, Raoul Tibes, Rami S. Komrokji, Jean Jacques Kiladjian, Guillermo Garcia-Manero, Attilio Orazi, Ruben Mesa, Jaroslaw P. Maciejewski, Pierre Fenaux, Raphael Itzykson, Ghulam Mufti, Eric Solary, Alan F. List

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

In the 2008 WHO classification, chronic myeloid malignancies that share both myelodysplastic and myeloproliferative features define the myelodysplastic/myeloproliferative group, which includes chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, atypical chronic myeloid leukemia, refractory anemia with ring sideroblasts and thrombocytosis, and myelodysplastic/myeloproliferative unclassified. With the notable exception of refractory anemia with ring sideroblasts and thrombocytosis, there is much overlap among the various subtypes at the molecular and clinical levels, and a better definition of these entities, an understanding of their biology and an identification of subtype-specific molecular or cellular markers are needed. To address some of these challenges, a panel comprised of laboratory and clinical experts in myelodysplastic/myeloproliferative was established, and four independent academic MDS/MPN workshops were held on: 9th March 2013, in Miami, Florida, USA; 6th December 2013, in New Orleans, Louisiana, USA; 13th June 2014 in Milan, Italy; and 5th December 2014 in San Francisco, USA. During these meetings, the current understanding of these malignancies and matters of biology, diagnosis and management were discussed. This perspective and the recommendations on molecular pathogenesis, diagnosis and clinical characterization for adult onset myelodysplastic/myeloproliferative is the result of a collaborative project endorsed and supported by the MDS Foundation.

Original languageEnglish (US)
Pages (from-to)1117-1130
Number of pages14
JournalHaematologica
Volume100
Issue number9
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Refractory Anemia
Thrombocytosis
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Juvenile Myelomonocytic Leukemia
Leukemia, Myelomonocytic, Chronic
San Francisco
Italy
Neoplasms
Education

ASJC Scopus subject areas

  • Hematology

Cite this

An international MDS/MPN working group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. / Mughal, Tariq I.; Cross, Nicholas C.P.; Padron, Eric; Tiu, Ramon V.; Savona, Michael; Malcovati, Luca; Tibes, Raoul; Komrokji, Rami S.; Kiladjian, Jean Jacques; Garcia-Manero, Guillermo; Orazi, Attilio; Mesa, Ruben; Maciejewski, Jaroslaw P.; Fenaux, Pierre; Itzykson, Raphael; Mufti, Ghulam; Solary, Eric; List, Alan F.

In: Haematologica, Vol. 100, No. 9, 01.01.2015, p. 1117-1130.

Research output: Contribution to journalArticle

Mughal, TI, Cross, NCP, Padron, E, Tiu, RV, Savona, M, Malcovati, L, Tibes, R, Komrokji, RS, Kiladjian, JJ, Garcia-Manero, G, Orazi, A, Mesa, R, Maciejewski, JP, Fenaux, P, Itzykson, R, Mufti, G, Solary, E & List, AF 2015, 'An international MDS/MPN working group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms', Haematologica, vol. 100, no. 9, pp. 1117-1130. https://doi.org/10.3324/haematol.2014.114660
Mughal, Tariq I. ; Cross, Nicholas C.P. ; Padron, Eric ; Tiu, Ramon V. ; Savona, Michael ; Malcovati, Luca ; Tibes, Raoul ; Komrokji, Rami S. ; Kiladjian, Jean Jacques ; Garcia-Manero, Guillermo ; Orazi, Attilio ; Mesa, Ruben ; Maciejewski, Jaroslaw P. ; Fenaux, Pierre ; Itzykson, Raphael ; Mufti, Ghulam ; Solary, Eric ; List, Alan F. / An international MDS/MPN working group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. In: Haematologica. 2015 ; Vol. 100, No. 9. pp. 1117-1130.
@article{fbc5e8fc36da43e9ae4ce5afd64ece07,
title = "An international MDS/MPN working group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms",
abstract = "In the 2008 WHO classification, chronic myeloid malignancies that share both myelodysplastic and myeloproliferative features define the myelodysplastic/myeloproliferative group, which includes chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, atypical chronic myeloid leukemia, refractory anemia with ring sideroblasts and thrombocytosis, and myelodysplastic/myeloproliferative unclassified. With the notable exception of refractory anemia with ring sideroblasts and thrombocytosis, there is much overlap among the various subtypes at the molecular and clinical levels, and a better definition of these entities, an understanding of their biology and an identification of subtype-specific molecular or cellular markers are needed. To address some of these challenges, a panel comprised of laboratory and clinical experts in myelodysplastic/myeloproliferative was established, and four independent academic MDS/MPN workshops were held on: 9th March 2013, in Miami, Florida, USA; 6th December 2013, in New Orleans, Louisiana, USA; 13th June 2014 in Milan, Italy; and 5th December 2014 in San Francisco, USA. During these meetings, the current understanding of these malignancies and matters of biology, diagnosis and management were discussed. This perspective and the recommendations on molecular pathogenesis, diagnosis and clinical characterization for adult onset myelodysplastic/myeloproliferative is the result of a collaborative project endorsed and supported by the MDS Foundation.",
author = "Mughal, {Tariq I.} and Cross, {Nicholas C.P.} and Eric Padron and Tiu, {Ramon V.} and Michael Savona and Luca Malcovati and Raoul Tibes and Komrokji, {Rami S.} and Kiladjian, {Jean Jacques} and Guillermo Garcia-Manero and Attilio Orazi and Ruben Mesa and Maciejewski, {Jaroslaw P.} and Pierre Fenaux and Raphael Itzykson and Ghulam Mufti and Eric Solary and List, {Alan F.}",
year = "2015",
month = "1",
day = "1",
doi = "10.3324/haematol.2014.114660",
language = "English (US)",
volume = "100",
pages = "1117--1130",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "9",

}

TY - JOUR

T1 - An international MDS/MPN working group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms

AU - Mughal, Tariq I.

AU - Cross, Nicholas C.P.

AU - Padron, Eric

AU - Tiu, Ramon V.

AU - Savona, Michael

AU - Malcovati, Luca

AU - Tibes, Raoul

AU - Komrokji, Rami S.

AU - Kiladjian, Jean Jacques

AU - Garcia-Manero, Guillermo

AU - Orazi, Attilio

AU - Mesa, Ruben

AU - Maciejewski, Jaroslaw P.

AU - Fenaux, Pierre

AU - Itzykson, Raphael

AU - Mufti, Ghulam

AU - Solary, Eric

AU - List, Alan F.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - In the 2008 WHO classification, chronic myeloid malignancies that share both myelodysplastic and myeloproliferative features define the myelodysplastic/myeloproliferative group, which includes chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, atypical chronic myeloid leukemia, refractory anemia with ring sideroblasts and thrombocytosis, and myelodysplastic/myeloproliferative unclassified. With the notable exception of refractory anemia with ring sideroblasts and thrombocytosis, there is much overlap among the various subtypes at the molecular and clinical levels, and a better definition of these entities, an understanding of their biology and an identification of subtype-specific molecular or cellular markers are needed. To address some of these challenges, a panel comprised of laboratory and clinical experts in myelodysplastic/myeloproliferative was established, and four independent academic MDS/MPN workshops were held on: 9th March 2013, in Miami, Florida, USA; 6th December 2013, in New Orleans, Louisiana, USA; 13th June 2014 in Milan, Italy; and 5th December 2014 in San Francisco, USA. During these meetings, the current understanding of these malignancies and matters of biology, diagnosis and management were discussed. This perspective and the recommendations on molecular pathogenesis, diagnosis and clinical characterization for adult onset myelodysplastic/myeloproliferative is the result of a collaborative project endorsed and supported by the MDS Foundation.

AB - In the 2008 WHO classification, chronic myeloid malignancies that share both myelodysplastic and myeloproliferative features define the myelodysplastic/myeloproliferative group, which includes chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, atypical chronic myeloid leukemia, refractory anemia with ring sideroblasts and thrombocytosis, and myelodysplastic/myeloproliferative unclassified. With the notable exception of refractory anemia with ring sideroblasts and thrombocytosis, there is much overlap among the various subtypes at the molecular and clinical levels, and a better definition of these entities, an understanding of their biology and an identification of subtype-specific molecular or cellular markers are needed. To address some of these challenges, a panel comprised of laboratory and clinical experts in myelodysplastic/myeloproliferative was established, and four independent academic MDS/MPN workshops were held on: 9th March 2013, in Miami, Florida, USA; 6th December 2013, in New Orleans, Louisiana, USA; 13th June 2014 in Milan, Italy; and 5th December 2014 in San Francisco, USA. During these meetings, the current understanding of these malignancies and matters of biology, diagnosis and management were discussed. This perspective and the recommendations on molecular pathogenesis, diagnosis and clinical characterization for adult onset myelodysplastic/myeloproliferative is the result of a collaborative project endorsed and supported by the MDS Foundation.

UR - http://www.scopus.com/inward/record.url?scp=84940921971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940921971&partnerID=8YFLogxK

U2 - 10.3324/haematol.2014.114660

DO - 10.3324/haematol.2014.114660

M3 - Article

VL - 100

SP - 1117

EP - 1130

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 9

ER -